ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Q4 2025 10-Q Quarterly Report
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 5, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ARROWHEAD PHARMACEUTICALS, INC. Q4 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $264.0M for Q1 FY2026, up $261.5M YoY from $2.5M in Q1 FY2025, driven by Sarepta, Novartis, Sanofi license agreements
- • Operating income $40.8M vs operating loss $(161.4)M YoY; net income $30.8M vs net loss $(173.1)M YoY; net income per diluted share $0.22 vs $(1.39)
Risk Factors
- • No new risk factors added this quarter compared to fiscal 2025 10-K
- • Most material risks remain consistent with those in fiscal 2025 10-K filing
ARROWHEAD PHARMACEUTICALS, INC. Q4 2025 Quarterly FinancialsXBRL
Revenue
$264M
▲ +10461.3% YoY
Net Income
$31M
▲ +117.8% YoY
Operating Margin
15.5%
▲ +647194bp YoY
Net Margin
11.7%
▲ +693507bp YoY
ROE
5.4%
▲ +33455bp YoY
Total Assets
$1.6B
▲ +58.3% YoY
EPS (Diluted)
$0.22
▲ +115.8% YoY
Operating Cash Flow
$13M
▲ +109.2% YoY
Source: XBRL data from ARROWHEAD PHARMACEUTICALS, INC. Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARROWHEAD PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.